Close Menu

genome mapping

The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.

The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.